[A14-26] Empagliflozin - Benefit assessment according to §35a Social Code Book V (dossier assessment)

Last updated 17.11.2014

Project no.:
A14-26

Commission:
Commission awarded on 15.08.2014 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Digestion, metabolism and hormones

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

17.11.2014

Empagliflozin in type 2 diabetes: added benefit not proven

Comparison of different treatment regimens made it impossible to clearly attribute the effect to the drug

Current document

Project no. Title Status
A16-12 Empagliflozin - Benefit assessment according to §35a Social Code Book V Commission completed
A14-50 Addendum to Commission A14-26 (empagliflozin) Commission completed

Federal Joint Committee (G-BA)

2015-02-05 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.